In a release, the Company said that Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis. "We are excited that Cobroxin is now officially available for sale," said Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corp. "Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States," he concluded. ((Comments on this story may be sent to health@closeupmedia.com)) For full details for NPHC click here.
![]()
Email Print Archives Feedback Email Article Link
Close X
Related News [NPHC]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|